|Bid||279.26 x 100|
|Ask||400.00 x 100|
|Day's Range||316.52 - 321.60|
|52 Week Range||244.28 - 330.00|
|PE Ratio (TTM)||20.93|
|Earnings Date||Oct 24, 2017 - Oct 30, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||333.02|
Analysts at Argus Research turned bullish on Bioverativ Inc (NASDAQ: BIVV ) as the company could establish itself as a profitable biotech within the hemophilia and blood disorders space. The firm's Jasper ...
This could indicate that investors who seek to profit from falling equity prices are not currently targeting BIIB. Over the last one-month, outflows of investor capital in ETFs holding BIIB totaled $1.03 billion.
Biogen Inc (NASDAQ:BIIB) stock had a fantastic start to September with a 15% rally. Clearly, this is a momentum stock, so it will never give us a clear signal for entry. More often than not, traders tend to overshoot with the price action of momentum stocks.